This is the authors' abstract. We don't add key points for this paper.
Advances in the molecular characterization of thyroid cancers have fueled the development of genetic and gene expression-based tests for thyroid fine-needle aspirations. Collectively, these tests are designed to improve the diagnostic certainty of thyroid cytology. This review summarizes the early published experience with the commercially available versions of these tests: the Afirma Gene Expression Classifier, ThyGenX (formerly miRInform)/ThyraMIR, and ThyroSeq. Key differences in testing approaches and issues regarding test performance and interpretation are also discussed.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Michiya Nishino (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: